Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in Botswana to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The market for these drugs has been steadily growing in recent years due to various factors.
Customer preferences: Patients in Botswana prefer bronchodilator drugs that are affordable, effective, and have minimal side effects. They also prefer drugs that are easy to administer and can be used for both short-term and long-term treatment.
Trends in the market: The market for bronchodilator drugs in Botswana has been growing due to the increasing prevalence of respiratory diseases in the country. According to the World Health Organization (WHO), the prevalence of asthma in Botswana is estimated to be around 15% among children and 10% among adults. Additionally, the rising awareness about the benefits of early diagnosis and treatment of respiratory diseases has also contributed to the growth of the market. The market is dominated by short-acting bronchodilators such as salbutamol and terbutaline, which are used for quick relief of asthma symptoms. However, long-acting bronchodilators such as formoterol and salmeterol are also gaining popularity due to their effectiveness in providing long-term relief from symptoms.
Local special circumstances: Botswana has a high burden of HIV/AIDS, which has been linked to an increased risk of respiratory infections and diseases. This has led to a higher demand for bronchodilator drugs in the country. Additionally, Botswana is a landlocked country with a small population, which means that the market for bronchodilator drugs is relatively small compared to other countries.
Underlying macroeconomic factors: The healthcare sector in Botswana has been growing in recent years due to increased government spending on healthcare infrastructure and services. This has led to improved access to healthcare services, including respiratory care. Additionally, the country's stable political environment and favorable business climate have attracted foreign investment, which has contributed to the growth of the healthcare sector. However, the market for bronchodilator drugs in Botswana is still largely dependent on imports, which makes it vulnerable to fluctuations in exchange rates and international trade policies.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
